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ABSTRACT: Vγ9/Vδ2 T-cells are activated by pyrophosphate-containing small
molecules known as phosphoantigens (PAgs). The presence of the pyrophosphate
group in these PAgs has limited their drug-like properties because of its instability
and polar nature. In this work, we report a novel and short Grubbs olefin metathesis-
mediated synthesis of methylene and difluoromethylene monophosphonate
derivatives of the PAg (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBP)
as well as their aryloxy diester phosphonamidate prodrugs, termed ProPAgens. These
prodrugs showed excellent stability in human serum (t1/2 > 12 h) and potent
activation of Vγ9/Vδ2 T-cells (EC50 ranging from 5 fM to 73 nM), which translated
into sub-nanomolar γδ T-cell-mediated eradication of bladder cancer cells in vitro.
Additionally, a combination of in silico and in vitro enzymatic assays demonstrated the
metabolism of these phosphonamidates to release the unmasked PAg mono-
phosphonate species. Collectively, this work establishes HMBP monophosphonate
ProPAgens as ideal candidates for further investigation as novel cancer immunotherapeutic agents.
■ INTRODUCTION
Vγ9/Vδ2 T-cells are the dominant subtype of human γδ T-
cells in adult peripheral blood.1 They are involved in immune
responses to many diseases such as tuberculosis, leprosy,
typhoid, malaria, and toxoplasmosis.1 Studies in primate
models have also implicated Vγ9/Vδ2 T-cells in immunity to
Mycobacterium tuberculosis.2 These cells have been shown to
target and lyse a diverse range of cancer cells in vitro.1
Together, these observations have made the Vγ9/Vδ2 subset a
major focus of investigation for the therapeutic exploitation of
γδ T-cells.3
To date, a handful of small molecule activators of Vγ9/Vδ2
T-cells have been reported. Among these are the two
aminobisphosphonate drugs, risedronate and zoledronate
(Figure 1), which are currently used clinically to treat
osteoporosis and some types of cancer.4−6 These agents
inhibit isopentenyl pyrophosphate (IPP) catabolism via
farnesyl diphosphate (FPP) synthase, leading to intracellular
IPP accumulation, which ultimately results in Vγ9/Vδ2 T-cell
activation.7−9 Beyond these two compounds, the microbially
derived phosphoantigen (PAg) (E)-4-hydroxy-3-methyl-but-2-
enyl pyrophosphate (HMBPP) and the host-derived PAg IPP
itself are both established Vγ9/Vδ2 T-cell activators (Figure
1).10,11 These are known to activate Vγ9/Vδ2 T-cells by
binding the type-1 transmembrane protein butyrophilin 3A1
(BTN3A1) that is expressed on target cells.12 Although the
binding site for these PAgs initially remained unclear amid
conflicting reports as to whether they bind the extracellular or
intracellular domains of this transmembrane protein, there is
now compelling evidence to support the notion that HMBPP
binds the intracellular B30.2 domain of butyrophilin 3A1,
triggering a conformational change.12−16 Although the
molecular events subsequent to this are unclear, PAg-mediated
activation is dependent upon target cells co-expressing
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Figure 1. Chemical structure of reported small molecule Vγ9/Vδ2 T-
cell activators; HMBPP (EC50: 60−500 pM),19−21 IPP (EC50: 1−10
μM),22,23 risedronate (EC50: 0.08−5 μM),24,25 and zoledronate
(EC50: 0.003−0.5 μM) [this work and Davey et al.20]
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BTN3A1 alongside a second family member, butyrophilin 2A1
(BTN2A1), with which it associates and which is able to
directly ligate the Vγ9Vδ2 T-cell receptor (TCR).17,18 One
plausible sensing mechanism involves PAg exposure regulating
BTN3A1-mediated recruitment of an additional molecule18
that in combination with BTN2A1, forms a “composite ligand”
for the Vγ9Vδ2 TCR complex, thereby triggering activation.18
Encouraged by the potency of the PAg HMBPP in activating
Vγ9/Vδ2 T-cells, EC50 = 60−500 pM,19−21 and given our
interest in developing phosphate- and phosphonate-containing
drugs,26−28 we previously reported the application of
McGuigan’s phosphoramidate prodrug technology29,30 to the
monophosphate derivative of HMBPP, that is, (E)-4-
hydroxybut-2-enyl phosphate (HMBP), as a means of
improving its drug-like properties.29 In this phosphoramidate
prodrug approach, the monophosphate or monophosphonate
groups are masked by an aryl group and an amino acid ester
(Figure 2), which are both enzymatically cleaved off inside
cells to release the monophosphate or monophosphonate
species.29 As these are prodrugs of PAgs, we previously20
termed them ProPAgens to distinguish them from ProTides,29
prodrugs of nucleotides. Although the HMBP ProPAgens that
we reported previously20 exhibited potent activation of Vγ9/
Vδ2 T-cells (EC50 = 0.45−10.62 nM), their stability was poor
(t1/2 < 30 min).
20 The observed instability was shown to be
because of the cleavage of the −P−O− bond of these
compounds.20 To circumvent this problem, we herein report
our application of McGuigan’s phosphoramidate prodrug
technology to HMBP methylene and difluoromethylene
monophosphonates to generate their aryloxy diester phospho-
namidate prodrugs (Figure 2).
■ RESULTS AND DISCUSSION
Design and Synthesis of HMBP Monophosphonate
ProPAgens. In the design of HMBP monophosphonates, we
switched the liable −O−PO(OH)2 to a more stable −CH2−
PO(OH)2 or −CF2−PO(OH)2 bond. The introduction of a
phosphonate bond (−CH2−PO(OH)2) instead of a phosphate
one (−O−PO(OH)2) is quite common in drug discovery and
has been used with success in addressing stability issues
observed with phosphate-containing compounds.31 A prime
example of this are the antiviral drugs cidofovir and adefovir.31
Although the change from a −O−PO(OH)2 bond to a
−CH2−PO(OH)2 bond achieves better stability, the pKa value
of the second deprotonation of the phosphonate group (pKa =
7.49) is significantly different from that of the phosphate group
(pKa = 6.31) (Figure 3).
32 As a result, this affects their full
ionization under physiological pH (<7.4) and, hence, their
binding to the target protein, which optimally requires the full
ionization of the phosphate group to bind a positively charged
pocket (arginine-rich) on the BTN3A1 intracellular B30.2
domain.16 To address this, switching the phosphate (−O−
PO(OH)2) bond to a difluoromethylene phosphonate
(−CF2−PO(OH)2) has emerged as a better substitution
because these have excellent stability in physiological environ-
ments coupled with a pKa value for the second deprotonation
(pKa = 5.5) as acidic as that of the native phosphate (Figure
3).32 Therefore, under physiological pH, the −CF2−PO(OH)2
will be fully deprotonated akin to natural phosphate groups
−O−PO(OH)2, and this ensures similar binding to that
achieved by the natural phosphate group.
With this in mind, we synthesized the ProPAgens of both
HMBP methylene and difluoromethylene monophosphonates
(4a−d and 9a−d, Scheme 1). Previously, the synthesis of
HMBP methylene monophosphonate prodrugs was achieved
in five steps starting from dimethyl homoprenylphosphonate,33
which itself has to be prepared in two steps from the
commercially available 3-methylbut-2-en-1-ol.19 Some of these
reactions are low yielding such as the oxidation of the side
chain to introduce HMBP’s side chain, the hydroxyl group.33
Notably, to date, no synthesis of HMBP difluoromethylene
monophosphonate prodrugs has been reported.
In order to accomplish the synthesis of HMBP methylene
and difluoromethylene monophosphonate prodrugs (4a−d
and 9a−d, Scheme 1), we employed the Grubbs olefin
metathesis34 in the construction of these prodrugs. Using
commercially available starting materials, our new synthetic
approach allowed the rapid and efficient synthesis of the PAg
ProPAgens in three steps for HMBP methylene mono-
phosphonate prodrugs (4a−d) and four steps for HMBP
difluoromethylene monophosphonate prodrugs (9a−d) as
shown in Scheme 1.
The synthesis of ProPAgens 4a−d started by treating the
commercially available diethyl 3-butenylphosphonate (1) with
bromotrimethylsilane (TMSBr) at room temperature to
remove the ethoxy groups and generate the phosphonic acid
derivative.35 This was followed by a chlorination reaction using
oxalyl chloride in the presence of a catalytic amount of DMF.
The product of this reaction, 2, was subsequently treated with
phenol in the presence of triethylamine and then with the
appropriate amino acid ester to yield phosphonamidates 3a−d
in moderate to good yields (38−61%). Next, these compounds
Figure 2. Chemical structures of HMBP ProPAgens (previous work)
and the ProPAgens of their phosphonate derivatives (this work) as
well as a general indication of their stability and Vγ9/Vδ2 T-cell
activation.
Figure 3. pKa values of phosphate and different phosphonate groups.
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underwent Grubbs olefin metathesis with 2-methyl-2-propenol
employing the Hoveyda−Grubbs second generation catalyst in
the presence of 1,4-benzoquinone to prevent alkene isomer-
ization.36 This gave ProPAgens 4a−d in good yields (57−
64%).
For the synthesis of ProPAgens 9a−d, the commercially
available diethyl (bromodifluoromethyl)phosphonate 5 was
reacted with allyl bromide in the presence of zinc and copper
bromide in DMF as reported.37 The generated compound, 6,
was subsequently chlorinated and then treated with phenol and
the appropriate amino acid ester to yield phosphonamidates
8a−d in moderate yields (24−46%) as described for the
synthesis of compounds 3a−d above. Subsequently, these
phosphonamidates were treated with 2-methyl-2-propenol in
the presence of Hoveyda−Grubbs second generation catalyst
and catalytic amounts of 1,4-benzoquinone.36 The final
ProPAgens 9a−d were generated in good yields (58−69%).
In terms of the design of the prodrugs, L-alanine was used as
the amino acid of choice in the synthesis of these ProPAgens
because it has historically shown optimum biological activity,30
while the phenol motif was chosen as it has been used
successfully in the discovery of two FDA-approved drugs:
sofosbuvir and tenofovir alafenamide.29 Four different ester
motifs were chosen in the synthesis of ProPAgens 4a−d and
9a−d, methyl (Me), isopropyl (iPr), tert-butyl (tBu), and
benzyl (Bn) because they show varying biological activities that
range from low (tBu) to high (Bn).20,26,29
Serum Stability of HMBP Monophosphonate ProPA-
gens. Because the motive for synthesizing the HMBP
monophosphonate ProPAgens was to address the poor stability
Scheme 1a
aReagents and conditions: (i) TMSBr, DCM, rt, 2 h then (COCl)2, DMF cat, DCM, rt, 18 h; (ii) a. Phenol, Et3N, DCM, −78 °C for 30 min then
rt, 3 h; b. Substituted L-alanine ester hydrochloride, Et3N, DCM, rt, 12 h, yields: 38−61%; (iii) 2-methyl-2-propenol, 1,4-benzoquinone, Hoveyda−
Grubbs catalyst 2nd generation, DCM, rt, yields: 57−64%; (iv) diethyl (bromodifluoromethyl)phosphonate, DMF, zinc powder, rt, N2, 3 h then
CuBr, allyl bromide, rt, 40 h; (v) (i) TMSBr, DCM, rt, 2 h then (COCl)2, DMF cat, DCM, rt, 18 h; (ii) a. Phenol, Et3N, DCM, −78 °C for 30 min
then rt, 3 h; b. Substituted L-alanine ester hydrochloride, Et3N, DCM, rt, 12 h, yields: 24−46%; and (iii) 2-methyl-2-propenol, 1,4-benzoquinone,
Hoveyda−Grubbs Catalyst 2nd generation, DCM, rt, yields: 58−69%.
Figure 4. Stability of HMBP monophosphonate ProPAgen 9a in human serum at 37 °C for 12 h as monitored by 31P NMR.
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observed with their parent HMBP monophosphate ProPA-
gens,20 upon the completion of their synthesis, we first studied
their stability in human serum. As an example, we incubated
the difluoromethylene ProPAgen 9a with human serum at 37
°C for 12 h and monitored the sample by 31P NMR, as we
reported previously.26 As shown in Figure 4, the 31P NMR
spectra of ProPAgen 9a showed six phosphorous peaks
because of the two diastereoisomers that arise from the chiral
phosphorous center, which is typical of these prodrugs, and the
phosphorous coupling with the fluorine atoms. Following the
addition of human serum and monitoring of the sample by 31P
NMR, these original 9a 31P NMR peaks remained present
through the 12 h of the study, and no new 31P NMR peaks
were observed. A similar stability profile was observed with the
methylene ProPAgen 4d (Figure S1).
Collectively, these data indicated the superior stability of
these compounds relative to that previously observed with
HMBP monophosphate ProPAgens.20 The observed −CH2−
PO(OH)2 and −CF2−PO(OH)2 groups’ stability profile is in-
line with what has been observed for difluoromethyl and
methyl phosphonates.31
Metabolism of HMBP Monophosphonate ProPAgens.
The breakdown of aryloxy triester phosphoramidate and
aryloxy diester phosphonamidate prodrugs is known to be
mediated by two enzymes: carboxypeptidase Y and a
phosphoramidase-type enzyme, for example, Hint-1 (Figure
5A).29 Indeed, upon cell entry, the breakdown of these
phosphonate masking groups is initiated by hydrolysis of the
ester motif by carboxypeptidase Y, and this generates a
carboxylate group (A), which performs a nucleophilic attack
onto the phosphonate group. This leads to the loss of the aryl
group and the formation of a highly unstable five-membered
heterocyclic ring (B), which is rapidly opened up by a water
molecule to generate the amidate metabolite C. Finally, a
phosphoramidase-type enzyme, for example, Hint-1 cleaves the
P−N bond and releases the monophosphonate species. As this
postulated mechanism of McGuigan’s phosphoramidate
prodrugs has been generated through extensive studies on
nucleoside monophosphate aryloxy triester phosphoramidate
prodrugs, we investigated whether this was the case for non-
nucleosides, PAg aryloxy diester phosphonamidate prodrugs in
this case. Thus, ProPAgen 9b was incubated in vitro with
recombinant carboxypeptidase Y at 37 °C, and the reaction
was then monitored by 31P NMR. As shown in Figure 5B, at t
= 0 h, the 31P NMR scan showed the presence of six
phosphorous peaks, δP = 9.25, 9.52, 9.71, 10.08, 10.19, and
10.51 ppm, as expected. However, 30 min after the addition of
recombinant carboxypeptidase Y and incubation at 37 °C, the
phosphorous peaks corresponding to ProPAgen 9b were
almost consumed and three prominent phosphorous peaks,
δP = 6.50, 6.90, and 7.20 ppm, appeared. These peaks remained
present throughout the 15 h period of this study. The
disappearance of the six phosphorous peaks corresponding to
ProPAgen 9b indicates that the carboxypeptidase Y cleaved off
the ester motif and triggered the breakdown of the aryloxy
diester phosphoramidate moiety as depicted in Figure 5A.
Given that the sample lacks Hint-1, the anticipated product
from this in vitro study is metabolite C (Figure 5A). This
notion was supported by the fact that the loss of the ester and
phenyl groups from the parent ProPAgen and the generation of
the corresponding metabolite C leads to the loss of the
chirality at the phosphorous center. Hence, the 31P NMR
would show only a triplet because of the phosphorous−
fluorine coupling, and such a splitting pattern was observed in
our study (Figure 5B). To confirm whether the product
generated after 15 h was metabolite C, the sample was
analyzed by LC−MS, and indeed, a new major peak was
detected by high-performance liquid chromatography (HPLC)
and this had a mass that corresponded to metabolite C (Figure
S2).
In order to probe whether metabolite C could be processed
by Hint-1 to cleave the P−N bond and release the
monophosphonate species,38−40 we performed in silico docking
of metabolite C into the cocrystal structure of Hint-1 with
AMP (Figure S3). Analysis of the different predicted poses
Figure 5. In vitro carboxypeptidase-mediated breakdown of HMBP
phosphonate ProPAgen 9b. (a) Postulated mechanism of aryloxy
diester prodrugs metabolism. (b) 31P NMR spectrum of ProPAgen 9b
alone and at different time points, following incubation with
recombinant carboxypeptidase Y at 37 °C for 15 h.
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indicated that the amidate moiety of metabolite C was
positioned in a pocket that included the key catalytic Hint-1
amino acid residues (serine 107, histidines 112 and 114)
(Figure S3). Such a position suggests that metabolite C is
likely to be processed by Hint-1 to release the unmasked
monophosphonate, in agreement with previous conclusions.27
Together, the in vitro carboxypeptidase Y assay and the
Hint-1 in silico docking support the metabolism of HMBP
phosphonate ProPAgens to release the unmasked mono-
phosphonate species.
Vγ9/Vδ2 T-cell Activation and Cancer Cells Lysis by
HMBP Monophosphonate ProPAgens. Once the syn-
thesis, stability, and metabolism of HMBP monophosphonate
ProPAgens were established, they were subsequently studied
for their ability to activate Vγ9/Vδ2 T-cells and lyse cancer
cells in vitro. For this, peripheral blood mononuclear cells
(PBMCs) containing Vγ9/Vδ2 T-cells derived from healthy
donors were incubated with increasing concentrations of
HMBPP, zoledronate, or HMBP ProPAgens 4a−d and 9a−d
(up to 100 μM) (Figure 6). Peripheral blood γδ T-cells lack
appreciable levels of surface CD69 or CD25 under steady-state
conditions, but TCR stimulation upregulates both T-cell
activation markers.41 PAg-responsive Vγ9/Vδ2 T-cells were
then assessed for the upregulation of CD69 and CD25.
The results showed that the natural PAg HMBPP exhibited
significant activation of Vγ9/Vδ2 T-cells, EC50 = 0.145 nM
(Figure 6C), comparable to its reported potency.19,21 Addi-
tionally, zoledronate showed a much weaker activation, EC50 ≈
3,060 nM as expected (Figure 6C). Initially, we tested the
activation of Vγ9/Vδ2 T-cells using all of the eight HMBP
phosphonate ProPAgens (4a−d and 9a−d) and employing
concentrations ranging from 10 pM to 100 μM (Figures 6A,B
and S4). For simplicity, the data presented in Figure 6A−C
only show the activation up to 10 μM, while a graphical
representation of the data up to 100 μM is provided in Figure
S4. All of the ProPAgens showed potent activation of Vγ9/Vδ2
T-cells with potencies (EC50) comparable to the natural PAg
HMBPP. Interestingly, two ProPAgens 4d and 9d, which are
the benzyl ester prodrugs, exhibited far more potent activation
of Vγ9/Vδ2 T-cells: even at 10 nM, these two prodrugs
achieved >50% activation of Vγ9/Vδ2 T-cells. To determine
the EC50 values of these compounds, we repeated the Vγ9/Vδ2
T-cells activation assay using sub-nanomolar concentrations
(from 1 attomolar [aM] to 100 μM) (Figure S5). The data
showed that ProPAgen 4d had an EC50 = 9.15 fM, whereas 9d
had an EC50 = 4.97 fM (Figure 6D), demonstrating that these
ProPAgens are 15,000−30,000-fold more potent than the PAg
HMBPP in the same assay. To the best of our knowledge, this
makes ProPAgens 4d and 9d the most potent small molecule
Vγ9/Vδ2 T-cells activators reported to date.
Notably, at the highest concentration studied (100 μM), the
activation of Vγ9/Vδ2 T-cells by ProPAgens 4d and 9d was
less than that achieved with 10 μM (Figure S4). This could be
explained by negative feedback mechanisms induced by
Figure 6. In vitro ProPAgen-mediated activation of Vγ9/Vδ2 T-cells, following overnight incubation with HMBPP, zoledronate, and HMBPP
ProPAgens. Levels of activation are represented as % of Vγ9/Vδ2 T-cells that are CD69+ CD25+. Data is shown as mean ± SE (n = 4). (A)
Activation of Vγ9/Vδ2 stimulated by ProPAgens 4a−d. (B) Activation of Vγ9/Vδ2 stimulated by ProPAgens 9a−d. (C) Activation of Vγ9Vδ2
stimulated by HMBPP and zoledronate. (D) EC50 values calculated based on the results of the activation assay. CLogP values were calculated using
ChemDraw.
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antigen overstimulation that lead to downregulation of the
TCR, subsequently resulting in lower expression of the CD25
activation marker.42
Although the potencies of compounds 4d and 9d are
significantly higher than the other HMBP ProPAgens studied
in this work (Figure 6D), this is consistent with other studies
of this type of prodrug when used as anticancer agents. An
example of this is the aryloxy triester phosphoramidate
prodrugs of the anticancer agent gemcitabine, where the
benzyl ester phosphoramidates exhibit potent sub-micromolar
potencies across four cancer cell lines compared to the
isopropyl ester prodrugs, which had an IC50 > 5 μM.
43
Additionally, HMBP methylene phosphoramidate prodrugs
using glycine as an amino acid have been shown to exhibit sub-
nanomolar activation of Vγ9/Vδ2 T-cells,33 and this was the
same with mixed aryl prodrugs of HMBP.44,45 Notably, glycine
phosphoramidates often generate less potent prodrugs
compared to the L-alanine counterparts.29 Thus, the sub-
nanomolar potencies of Vγ9/Vδ2 T-cell activation by HMBP
prodrugs seems to be consistent and correlates with the
lipophilicity of the prodrugs.
Considering the structure−activity relationship (SAR) of
our HMBP ProPAgens, we did not observe significant
differences between the methyl and difluoromethyl phospho-
nate ProPAgens, while the Vγ9/Vδ2 T-cell activation potency
varied with the ester motif used. Indeed, ProPAgens with the
benzyl ester groups (4d and 9d) exhibited the most potent
activation of Vγ9/Vδ2 T-cells, followed by those with methyl
and isopropyl ester groups, and the tBu-bearing ProPAgens
exhibited the least potency in activating Vγ9/Vδ2 T-cells
within the series presented here.
Such an influence of the ester group on the biological
activity of this type of phosphonamidate prodrugs is consistent
with the established SAR of these prodrugs.29 The difference in
biological activity in such prodrugs is because of the differential
lipophilicity between these compounds and the efficiency of
the esterases in hydrolyzing the ester groups. For instance, it is
now well-established that phosphonamidates with a benzyl
ester often show the best biological activity because they often
have the highest lipophilicity, which facilitates their efficient
passive uptake into cells as well as rapid hydrolysis of this ester
group by esterases.29
In contrast to the benzyl moieties, the tBu esters of
phosphonamidates are known to be metabolized relatively
slowly by esterases, which explains their relatively poor
biological activity as compared to their benzyl ester
phosphonamidates. This may also explain the superior Vγ9/
Vδ2 T-cell activation by the benzyl ester ProPAgens 4d and 9d
compared to the other studied ProPAgensthe 20 h
activation assay described here is often sufficient for the
benzyl ester prodrugs to be metabolized, while it may be of too
short duration for the other nonbenzyl ester ProPAgens to be
metabolized to levels that generate intracellular concentrations
of the monophosphonate species sufficient to induce potent
Vγ9/Vδ2 T-cell activation. Indeed, classically, the potency of
aryloxy triester phosphoramidates is determined after 48 or 72
h, and in such studies, the nonbenzyl ester aryloxy triester
phosphoramidates (apart from the tBu esters) show potent
pharmacological activity.43,46
Given the high potency of HMBPP ProPAgen presented in
this work, we subsequently studied their specificity toward the
activation of Vγ9/Vδ2 T-cells. For this, we repeated the same
Figure 7. Cytotoxicity of Vγ9/Vδ2 T-cells toward ProPAgen-treated T24 cells. % killing represents % GFP + eFluor780+ cells (i.e. dead T24 cells).
(A) Cytotoxicity of Vγ9/Vδ2 T-cells toward T24 cells treated with ProPAgens 4c, 4d, 9c, and 9d at different effector/target ratios. Ratio 0:1 refers
to the basal effect of ProPAgens on T24 cells in the absence of effectors. (B,C) Cytotoxicity of ProPAgens 4c, 4d, 9c, and 9d (used at 10 pM)
compared to the 10 pM HMBPP-induced effect after subtracting the basal cytotoxic effect of Vγ9/Vδ2 on untreated T24 cells. Data is shown as
mean ± SE (n = 3). Statistical analysis was performed using one-way ANOVA and Tukey’s multiple comparisons test. *p < 0.05.
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Vγ9/Vδ2 T-cell activation assay using ProPAgens 4d and 9d
(1 aM and 100 μM concentrations) and also, as a specificity
control, we assessed the activation of CD8+ αβ T-cells, which
are activated by peptides.47 As expected, our data confirmed
that these prodrugs did not induce any activation of αβ T-cells
(Figure S6). The specificity of these HMBP prodrugs is,
therefore, in line with previous observations.20
Encouraged by the potency and specificity of our HMBP
ProPAgens, especially 4d and 9d, we subsequently studied
their ability to sensitize the urinary bladder carcinoma cell line
T24 for targeted killing by in vitro expanded Vγ9/Vδ2 T-cells.
In brief, T24 cells were retrovirally transduced to express GFP.
These GFP + T24 cells were incubated in media containing 10
pM HMBPP or the indicated HMBPP ProPAgens for a period
of 4 h. Media-only treated controls (no drug) were also
included. The cells were then washed and cocultured with ex
vivo expanded Vγ9/Vδ2 T-cells overnight at different effector/
target ratios, and the viability of GFP + T24 cells was then
measured on the following day. In the absence of effectors
(Vγ9/Vδ2 T-cells), ProPAgen-pulsed T24 cells were poorly
targeted, but upon pulsing for 4 h with Vγ9/Vδ2 T-cells, T24
cells were specifically lysed with increasing effector/target
ratio, particularly with ProPAgens 4d and 9d (Figure 7A). In
addition, the sensitizing effects of ProPAgens 4d and 9d are
evidently much more potent in comparison to HMBPP and
the tBu ester ProPAgens 4c and 9c (Figure 7B,C). Notably,
ProPAgen 9d showed more significant sensitizing effects
compared to HMBPP and ProPAgen 9c at 1:1 effector/target
ratio (Figure 7B). Collectively, these results are consistent with
our previous20 and current findings that benzyl ester
ProPAgens are the most potent activators of Vγ9/Vδ2 T-
cells based on the data generated by in vitro activation assays,
while, alternatively, the tBu ester ProPAgens are comparatively
less potent.
■ CONCLUSIONS
A series of HMBP methylene and difluoromethylene mono-
phosphonate ProPAgens were synthesized using the Grubbs
olefin metathesis, the first report of this approach in
synthesizing the HMBP phosphonate core. These ProPAgens
exhibited superior serum stability compared to their phosphate
ProPAgen derivatives, and which we have previously
reported.20 Critically, these prodrugs were specific and potent
activators of Vγ9/Vδ2 T-cells (femtomolar EC50) in PBMC
assays and this translated into potent sensitization of the
urinary bladder carcinoma cell line T24 to Vγ9/Vδ2 T-cell-
mediated lysis. In PBMC assays, although it is unclear which
cells take up the ProPAgens, it has previously been reported
that aminobisphosphonates such as zoledronate, as well as the
PAg HMBPP, are taken up and “presented” to Vγ9Vδ2 T-cells
by monocytes and dendritic cells (DCs).48,49 While this may
also be the case for ProPAgens, it is likely they are taken up
and processed by a wider range of cells, as they are more
lipophilic than zoledronate and HMBPP, allowing intracellular
access through diverse cell membranes likely via passive
diffusion. Enhanced and potentially broadened uptake in
PBMC could be responsible for their higher potency compared
to HMBPP and zoledronate. Regarding their ability to directly
sensitize cancer cells for Vγ9/Vδ2 T-cell-mediated lysis, in the
future, it will be beneficial to explore the potency of these
ProPAgens against a wider range of cancer targets, as well as
assessing the tumor selectivity in comparison to healthy cells.
Of relevance to future efforts, substantial levels of Vγ9/Vδ2 T-
cell-mediated killing were observed in T24 killing assays in the
absence of ProPAgen sensitization. This is likely to be affected
by several factors, including the activation state of the γδ T-
cells, the levels of endogenous PAg in target cells (e.g.,
isopentenyl pyrophosphate50), and the presence on target cells
of ligands for natural killer cell receptors expressed on Vγ9/
Vδ2 T-cells such as the Natural Killer Group 2D (NKG2D)
and DNAX Accessory Molecule-1 (DNAM1).51 These factors
in combination will likely exert an important influence on Vγ9/
Vδ2 T-cell effector responses, but have substantial potential to
synergize with ProPAgen-mediated sensitization.
Collectively, the stability and potency profiles of the new
HMBP phosphonate ProPAgens presented in this work make
them highly promising candidates for in vivo safety and efficacy
studies, and future development as new immunotherapeutics
for treating challenging cancers and infections that can be
targeted by Vγ9/Vδ2 T-cell responses. Regarding their clinical
application, these ProPAgens could conceivably either be
employed as part or subsequent to a clinical regimen to expand
γδ T-cells in vivo or, alternatively, they could be administered
to patients receiving adoptive cell therapy with ex vivo-
expanded γδ T-cells, to directly augment Vγ9/Vδ2 T-cell-
mediated antitumor activity.
■ EXPERIMENTAL SECTION
General Information. All reagents and solvents were of general
purpose or analytical grade and were purchased from Sigma-Aldrich
Ltd., Fisher Scientific, Fluorochem, or Acros. 31P, 1H, and 13C NMR
data were recorded on a Bruker AVANCE DPX500 spectrometer
operating at 202, 500, and 125 MHz, respectively. Chemical shifts (δ)
are quoted in ppm, and J values are quoted in Hz. In reporting
spectral data, the following abbreviations were used: s (singlet), d
(doublet), t (triplet), q (quartet), dd (doublet of doublets), td (triplet
of doublets), and m (multiplet). All of the reactions were carried out
under a nitrogen atmosphere and were monitored using analytical
thin layer chromatography on precoated silica plates (kiesel gel 60
F254, BDH). Compounds were visualized by illumination under UV
light (254 nm) or by the use of KMnO4 stain followed by heating.
Flash column chromatography was performed with silica gel 60
(230−400 mesh) (Merck). HPLC was carried out on a SHIMADZU
Prominence-i quaternary low-pressure gradient pump with a
Prominence-i UV detector (190 to 700 nm). All solvents for HPLC
were HPLC grade purchased from Fisher Scientific. HPLC data
analysis was performed using the SHIMADZU Lab solutions software
package. The purity of the tested ProPAgens was determined by
HPLC, and they were all of ≥95% purity.
But-3-en-1-ylphosphonic Dichloride (2). Trimethylsilylbromide
(13.72 mL, 104.06 mmol, 10 equiv) was slowly added over 30 min to
diethylbut-3-en-1-yl phosphonate 1 (2 g, 10.40 mmol, 1 equiv) in
DCM (50 mL) under nitrogen at room temperature. The mixture was
stirred for 2 h followed by the removal of volatiles under reduced
pressure to obtain a yellow liquid δP NMR (202 MHz, CDCl3): 24.70.
This was then dissolved in 50 mL of DCM, two drops of dry DMF
were added, the mixture was cooled to 0 °C. Oxalyl chloride (2.68
mL, 31.20 mmol, 3 equiv) was then added dropwise, and the reaction
mixture was allowed to warm to room temperature and stirred for 18
h. The volatiles were evaporated, and additional DCM (10 mL) was
evaporated three more times to give the crude product (1.79 g, 100%)
as a brown liquid which was used in the next step without further
purification. δP NMR (202 MHz, CDCl3): 49.66.
General Procedure 1. Synthesis of Allylphosphonoami-
dates 3a−d. The crude product but-3-en-1-ylphosphonic dichloride
(2) was dissolved in 5 mL of DCM and added dropwise to a solution
of phenol (1 equiv), dry Et3N (2 equiv), and DCM (10 mL) at −78
°C. After stirring at −78 °C for 30 min, the reaction mixture was
allowed to warm to room temperature, and the stirring was continued
for another 3 h. Once the reaction is complete as indicated by 31P
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NMR [δP NMR (202 MHz, CDCl3): ∼39.93], the mixture was
filtered, and the volatiles were removed under reduced pressure and
washed twice with Et2O, which was subsequently removed under
reduced pressure to give a crude oil. This product was then dissolved
in DCM (10 mL) and was added dropwise over 15 min to a stirring
mixture of L-alanine ester hydrogen chloride (1 equiv) and dry Et3N
(2 equiv) in dry DCM (10 mL) under nitrogen at −78 °C. After
stirring at −78 °C for 30 min, the reaction was allowed to warm to
room temperature and was left stirring overnight. The solvents were
removed under reduced pressure, and the mixture was filtered and
washed with Et2O, which was then removed under reduced pressure
to give a crude oil. The final products were then purified by column
chromatography (6:4 Hex/EtOAc) as colorless oils.
Methyl (but-3-en-1-yl(phenoxy)phosphoryl)-L-alaninate (3a).
Synthesized following general procedure 1 using phenol (0.210 g,
2.23 mmol, 1 equiv) and L-alanine methyl ester hydrogen chloride
(0.373 g, 2.23 mmol, 1 equiv) to give product 3a (0.248 g, 38%) as a
colorless oil. δP NMR (202 MHz, CDCl3): 30.88, 31.22. δH NMR
(500 MHz, CDCl3): 7.30 (m, 2H, Ar), 7.10 (m, 3H, Ar),5.82 (m, 1H,
CH2CH), 5.00 (m, 2H, CH2CH), 4.11−3.86 (m, 1H,CH−NH),
3.60 (d, J = 6.6 Hz, 3H, OCH3), 3.18 (m, 1H,NH), 2.48−2.27 (m,
2H,CH−CH2), 1.92 (m, 2H, CH2−P), 1.21 (2 d, J = 7.1 Hz, 3H,
CH−CH3). δC NMR (126 MHz, CDCl3): 174.68 (d, J = 6.3 Hz, C
O), 174.38 (d, J = 5.1 Hz, CO), 150.72 (d, J = 9.1 Hz), 150.51 (d, J
= 9.4 Hz), 129.78, 124.78 (d, J = 5.5 Hz, CHCH2), 120.86 (d, J =
4.6 Hz, C−Ar), 120.71 (d, J = 4.7 Hz), 115.56, 52.52 (d, J = 3.1 Hz,
CH3−O), 49.58 (d, J = 14.7 Hz, CH−NH), 27.88 (d, J = 130.9 Hz,
CH2−P) 27.60 (d, J = 131.6 Hz, CH2−P), 26.59 (d, J = 4.1 Hz,
CH2−CH2−P), 21.68 (2 d, J = 4.3 Hz, CHCH3).
Isopropyl (but-3-en-1-yl(phenoxy)phosphoryl)-L-alaninate (3b).
Synthesized following general procedure 1 using phenol (0.210 g, 2.23
mmol, 1 equiv) and L-alanine isopropyl ester hydrogen chloride
(0.373 g, 2.23 mmol, 1 equiv) to give product 3b (0.348 g, 48%) as a
colorless oil. δP NMR (202 MHz, CDCl3): 30.93, 31.24. δH NMR
(500 MHz, CDCl3): 7.30 (m, 2H, Ar), 7.21 (m, 3H, Ar), 5.81 (m,
1H, CH2CH), 5.11 (m, 2H, CH2CH), 4.96 (m, 1H, CH−iPr),
4.04−3.94 (m, 1H, CH−NH), 3.21 (m, 1H, NH), 2.45 (m, 2H, 
CH−CH2), 2.02−1.88 (m, 2H, CH2−P), 1.29−1.18 (m, 9H, CH3−
CH−NH, CH−iPr). δC NMR (126 MHz, CDCl3): 173.67 (d, J = 6.3
Hz, CO), 150.74 (d, J = 9.1 Hz), 129.76 (d, J = 6.7 Hz), 124.73 (d,
J = 5.0 Hz), 120.86 (d, J = 4.6 Hz), 120.69 (d, J = 4.6 Hz), 115.50,
69.23 (d, J = 5.6 Hz, CH−iPr), 49.75 (d, J = 9.5 Hz, CH−NH), 27.89
(d, J = 130.9 Hz, CH2−P), 27.54 (d, J = 131.4 Hz, CH2−P), 26.74 (d,
J = 4.3 Hz, CH2−CH2−P), 26.57 (d, J = 4.0 Hz, CH2−CH2−P),
21.58 (2 d, J = 4.4 Hz, CHCH3).
tert-Butyl (but-3-en-1-yl(phenoxy)phosphoryl)-L-alaninate (3c).
Synthesized following general procedure 1 using phenol (0.210 g, 2.23
mmol, 1 equiv) and L-alanine tert-butyl ester hydrogen chloride
(0.405 g, 2.23 mmol, 1 equiv) to give product 3c (0.461 g, 61%) as a
colorless oil. δP NMR (202 MHz, CDCl3): 30.95, 31.21. δH NMR
(500 MHz, CDCl3): 7.32 (m, 2H, Ar), 7.20 (m, 3H, Ar), 5.87 (m,
1H, CH2CH), 5.12 (m, 2H, CH2CH), 4.00−3.86 (m, 1H, CH−
NH), 3.26 (m, 1H, NH), 2.45 (m, 2H,CH−CH2), 2.04−1.85 (m,
2H, P−CH2), 1.42 (s, 9H, tBu-H), 1.22 (2 d, J = 7.2 Hz, 3H, CH−
CH3). δC NMR (126 MHz, CDCl3): 173.13 (d, J = 5.5 Hz, CO),
150.77 (d, J = 9.2 Hz), 137.43 (d, J = 7.1 Hz), 137.32 (d, J = 7.6 Hz),
129.76 (d, J = 6.2 Hz), 124.71 (d, J = 4.0 Hz), 120.88 (d, J = 4.6 Hz),
120.72 (d, J = 4.7 Hz), 115.47, 81.99 (d, J = 8.2 Hz), 60.54, 50.18 (d,
J = 4.0 Hz, CH−NH), 28.05, 27.91 (d, J = 131.6 Hz, CH2−P), 27.20
(d, J = 130.2 Hz, CH2−P), 21.82 (2 d, J = 4.2 Hz, CHCH3).
Benzyl (but-3-en-1-yl(phenoxy)phosphoryl)-L-alaninate (3d).
Synthesized following general procedure 1 using phenol (0.210 g,
2.23 mmol, 1 equiv) and L-alanine benzyl ester hydrogen chloride
(0.405 g, 2.23 mmol, 1 equiv) to give product 3d (0.461 g, 55%) as a
colorless oil. δP NMR (202 MHz, CDCl3): 30.85, 31.21. δH NMR
(500 MHz, CDCl3): 7.38−7.27 (m, 7H, Ar), 7.21−7.18 (m, 2H, Ar),
7.16−7.09 (m, 1H, Ar), 5.85 (m, 1H, CH2CH), 5.04 (m, 4H,
CH2CH, −OCH2), 4.28−4.03 (m, 1H, CH−NH), 3.24 (m, 1H,
NH), 2.56−2.34 (m, 2H,CH−CH2), 2.08−1.82 (m, 2H, P−CH2),
1.24 (2 d, J = 7.1 Hz, 3H, CH−CH3). δC NMR (126 MHz, CDCl3):
173.74 (d, J = 5.2 Hz, CO), 150.70 (d, J = 9.1 Hz), 137.35, 135.40
(d, J = 6.7 Hz), 129.79 (d, J = 6.1 Hz), 128.79 (d, J = 2.8 Hz), 128.64
(d, J = 6.4 Hz), 128.33, 120.86 (d, J = 4.6 Hz), 120.68 (d, J = 4.7 Hz),
115.55, 67.31 (d, J = 3.0 Hz, CH2−O), 49.72 (d, J = 11.1 Hz, CH−
NH), 27.88 (d, J = 130.7 Hz, CH2−P), 27.57(d, J = 131.3 Hz, CH2−
P), 26.74 (d, J = 4.3 Hz, CH2−CH2−P), 26.57 (d, J = 4.1 Hz, CH2−
CH2−P), 21.70 (2 d, J = 4.4 Hz, CHCH3).
General Procedure for the Synthesis of Phosphonoamidates
through Hoveyda−Grubbs Cross Metathesis. To a solution of
allylphosphonoamidates 3a−d (1 equiv) and 2-methyl-2-propen-1-ol
(85 μL, 1 mmol, 2 equiv), 1,4-benzoquinone (5.40 mg, 10 mol %) in
dry DCM (10 mL) was added to Hoveyda−Grubbs catalyst 2nd
generation (23.5 mg, 0.038 mmol, 7.5 mol %). The catalyst was added
in three equal portions of 2.5 mol % (7.8 mg, 0.013 mmol) at t = 0, 2,
and 4 h over the course of the reaction. The solution was then heated
to reflux at 45 °C under a nitrogen atmosphere for 18 h. After cooling
to room temperature, a scoop of activated carbon was added, and the
mixture stirred for another 2 h and then filtered through a Celite pad.
Volatiles were evaporated, and the residue was purified by extensive
silica gel column chromatography (hexane/EtOAc, 7:3 to 0:10) to
give 4a−d as colorless oils.
Methyl (((E)-5-hydroxy-4-methylpent-3-en-1-yl)(phenoxy)-
phosphoryl)-L-alaninate (4a). Synthesized following general proce-
dure 2 using 3a (150 mg, 0.5 mmol, 1 equiv) to give 4a (91 mg, 57%)
as a colorless oil. δP NMR (202 MHz, CDCl3): 30.89, 31.31. δH NMR
(500 MHz, CDCl3): 7.31 (m, 2H, Ar), 7.18 (m, 3H, Ar), 5.48 (m,1H,CH), 4.24−3.98 (m, 3H, CH2OH, CH−NH), 3.68 (d, J = 7.9 Hz,
3H, OCH3), 3.39−3.18 (m, 1H, NH), 2.55−2.41 (m, 2H, CH−
CH2), 2.12−1.87 (m, 2H, CH2−P), 1.71 (d, J = 6.6 Hz, 3H,
CH3(CH2)C), 1.27 (2 × d, J = 7.1 Hz, 3H, CH−CH3). δC NMR
(126 MHz, CDCl3): 176.71 (d, J = 5.9 Hz, CO), 150.72, 129.81 (d,
J = 6.9 Hz), 124.81 (d, J = 8.6 Hz, CHCH2), 124.17, 124.04,
120.94, 120.69 (d, J = 4.6 Hz), 68.56 (d, J = 9.1 Hz, CH2−OH),
52.64 (d, J = 3.5 Hz, CH3−O), 49.51 (d, J = 4.1 Hz, CH−NH), 28.33
(d, J = 129.6 Hz CH2−P), 28.06 (d, J = 130.2 Hz, CH2−P), 21.86 (2
d, J = 4.9 Hz, CHCH3), 21.00 (d, J = 4.8 Hz, CH2−CH2−P), 20.89
(d, J = 4.4 Hz, CH2−CH2−P),13.87. HRMS (ES+, m/z): calcd for
(M + Na)+ C16H24NO5NaP, 364.1290; found, 364.1293. HPLC
(reverse-phase) 0.5 mL/min MeOH/H2O 70:30 in 12 min, λ = 254
nm, tRt = 5.36 min (96.5%).
Isopropyl (((E)-5-hydroxy-4-methylpent-3-en-1-yl)(phenoxy)-
phosphoryl)-L-alaninate (4b). Synthesized following general proce-
dure 2 using 3b (0.150 g, 0.46 mmol, 1 equiv) to give product 4b (97
mg, 59%) as a colorless oil. δP NMR (202 MHz, CDCl3): 31.11,
31.49. δH NMR (500 MHz, CDCl3): 7.28 (m, 2H, Ar), 7.20 (m, 3H,
Ar), 5.46 (m, 1H,CH), 4.95 (m, 1H, CH−iPr), 4.08−3.79 (m, 3H,
CH2OH, CH−NH), 3.47−3.25 (m, 1H, NH), 2.51−2.35 (m, 2H,
CH−CH2), 2.02−1.85 (m, 2H, CH2−P), 1.73−1.56 (d, J = 6.0 Hz,
3H, CH3(CH2)C), 1.35−1.08 (m, 9H, CH3−CH−NH, CH−iPr).
δC NMR (126 MHz, CDCl3): 173.62 (d, J = 5.8 Hz, CO), 150.74
(d, J = 9.0 Hz),136.76, 124.75, 123.95 (d, J = 5.4 Hz), 123.84 (d, J =
6.9 Hz), 120.90 (d, J = 4.5 Hz), 120.67 (d, J = 4.6 Hz),119.83, 115.58,
69.41 (d, J = 4.7 Hz, CH−iPr) 68.39 (d, J = 7.0 Hz, CH2−OH),
49.65, 28.36 (d, J = 129.7 Hz, CH2−P), 27.92 (d, J = 131.1 Hz, CH2−
P), 21.83 (2 d, J = 6.2 Hz, CHCH3), 20.90 (d, J = 4.4 Hz, CH2−
CH2−P), 20.84 (d, J = 4.4 Hz, CH2−CH2−P),13.84.HRMS (ES+, m/
z): calcd for (M + Na)+ C18H28NO5NaP, 392.1603; found, 392.1613.
HPLC (reverse-phase) 0.5 mL/min MeOH/H2O 70:30 in 12 min, λ
= 254 nm, Rt = 5.23 min (98%).
tert-Butyl (((E)-5-hydroxy-4-methylpent-3-en-1-yl)(phenoxy)-
phosphoryl)-L-alaninate (4c). Synthesized following general proce-
dure 2 using 3c (0.150 g, 0.44 mmol, 1 equiv) to give product 4c (108
mg, 64%) as a colorless oil. δP NMR (202 MHz, CDCl3): 31.05,
31.42. δH NMR (500 MHz, CDCl3): 7.30 (m, 2H, Ar), 7.17 (m,
3H,Ar), 5.46 (m, 1H, CH), 4.17−3.78 (m, 3H, CH2OH, CH−
NH), 3.41−3.18 (m, 1H, NH), 2.60−2.30 (m, 2H, CH−CH2),
2.01−1.87 (m, 2H, CH2−P), 1.69 (d, J = 6.8 Hz, 3H, CH3(CH2)-
C), 1.42 (s, 9H, tBu), 1.27 (2 d, J = 7.9 Hz, 3H, CH−CH3). δC
NMR (126 MHz, CDCl3): 173.34 (d, J = 6.0 Hz, CO), 150.79 (d, J
= 9.0 Hz), 136.81 (d, J = 9.6 Hz), 115.59, 82.22 (d, J = 5.6 Hz), 68.45
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(d, J = 10.4 Hz, CH2−OH), 50.07 (d, J = 4.5 Hz, CH−NH), 28.01
(d, J = 129.7 Hz, CH2−P), 27.26 (d, J = 130.4 Hz, CH2−P), 21.98 (d,
J = 3.8 Hz, CHCH3), 20.97 (d, J = 4.7 Hz, CH2−CH2−P), 20.88 (d, J
= 4.4 Hz, CH2−CH2−P), 13.86 (CH3). HRMS (ES+, m/z): calcd for
(M + Na)+ C19H30NO5NaP, 406.1759; found, 406.1762. HPLC
(reverse-phase) 0.5 mL/min MeOH/H2O 70:30 in 12 min, λ = 254
nm, Rt = 5.41 min (97%).
Benzyl (((E)-5-hydroxy-4-methylpent-3-en-1-yl)(phenoxy)-
phosphoryl)-L-alaninate (4d). Synthesized following general proce-
dure 2 using 3d (0.150 g, 0.4 mmol, 1 equiv) to give product 4d (100
mg, 59%) as a colorless oil. δP NMR (202 MHz, CDCl3): 30.90,
31.32, δH NMR (500 MHz, CDCl3): 7.39−7.28 (m, 7H, Ar), 7.22−
7.17 (m, 2H,Ar), 7.12 (m, 1H, Ar), 5.44 (m, 1H, CH), 5.09 (m,
2H, OCH2), 4.22−3.86 (m, 3H, m, 3H, CH2OH, CH−NH), 3.49−
3.17 (m, 1H, NH), 2.64−2.36 (m, 2H,CH−CH2), 2.04−1.80 (m,
2H, CH2−P), 1.69 (d, J = 6.8 Hz, 3H, CH3(CH2)C), 1.33 (2 d, J =
7.0 Hz, 3H, CH−CH3). δC NMR (126 MHz, CDCl3): 176.76, 129.81
(d, J = 7.4 Hz), 128.75 (d, J = 14.9 Hz), 128.39, 124.77, 124.15 (d, J =
15.0 Hz), 120.93−120.84, 120.67 (d, J = 4.7 Hz), 68.57 (d, J = 9.6
Hz), 67.42 (d, J = 2.9 Hz), 49.65, 28.05 (d, J = 129.9 Hz), 21.77 (d, J
= 4.1 Hz), 20.87 (d, J = 4.4 Hz), 13.87. HRMS (ES+, m/z): calcd for
(M + Na)+ C22H28NO5NaP, 440.1603; found, 440.1609. HPLC
(reverse-phase) 0.5 mL/min MeOH/H2O 70:30 in 12 min, λ = 254
nm, Rt = 5.18 min (95%).
Diethyl (1,1-difluorobut-3-en-1-yl)phosphonate (6).37 Anhydrous
DMF (20 mL) was added to a 250 mL round bottom flask containing
activated zinc powder (2.50 g, 38.23 mmol, 1 equiv) under nitrogen.
This was followed by slow dropwise addition of diethyl
(bromodifluoromethyl)phosphonate (6.80 mL, 38.23 mmol, 1
equiv), and the mixture was stirred for 3 h at room temperature.
CuBr (5.48 g, 38.23 mmol, 1 equiv) was added followed by slow
dropwise addition of allyl bromide (3.96 mL, 45.87 mmol, 1.2 equiv)
to prevent exothermic reaction. After stirring for 40 h, the mixture was
filtered and then partitioned between DCM and 10% aqueous NH4Cl.
The aqueous phase was extracted three times with DCM. The
combined organic phases were dried over anhydrous MgSO4 and
concentrated under reduced pressure, and the residue obtained was
purified by column chromatography using 20% EtOAc in hexane to
give 6 (5.41 g, 62%) as a pale-yellow oil. δP NMR (202 MHz,
CDCl3): 6.93 (t, J = 107.4 Hz). δH NMR (500 MHz, CDCl3): 5.84
(m, 1H, CH), 5.26 (m, 2H, CH2), 4.32−4.21 (m, 4H, 2 ×
OCH2CH3), 2.82 (m, 2H,CH−CH2), 1.37 (t, J = 7.1 Hz, 6H, 2 ×
OCH2CH3).
(1,1-Difluorobut-3-en-1-yl)phosphonic Dichloride (7). Synthe-
sized as described for 2 using 6 (2.5 g, 10.95 mmol, 1 equiv) to
give the crude product 7 (2.28 g, 100%) as a brown liquid, which was
used in the next step without further purification. δP NMR (202 MHz,
CDCl3): 31.56 (t, J = 138.8 Hz).
Methyl ((1,1-difluorobut-3-en-1-yl)(phenoxy)phosphoryl)-L-ala-
ninate (8a). Synthesized following general procedure 1 using phenol
(0.210 g, 2.23 mmol, 1 equiv) and L-alanine methyl ester hydrogen
chloride (0.261 g, 1.87 mmol, 1 equiv) to give product 8a (0.150 g,
24%) as a colorless oil. δP NMR (202 MHz, CDCl3): 9.05 (dd, J =
101.1, 49.9), 8.41 (dd, J = 100.0, 51.1 Hz). δH NMR (500 MHz,
CDCl3): 7.35 (m, 2H, Ar), 7.21 (m, 3H, Ar), 5.89 (m, 1H, CH2
CH), 5.29 (m, CH2CH), 4.14 (m, 1H, CH−NH), 3.69 (d, J = 6.6
Hz, 3H, OCH3),3.64 (m, 1H, NH), 3.13−2.84 (m, 2H, CH−
CH2), 1.38 (2 × d, 7.1 Hz, 3H, CH−CH). δC NMR (126 MHz,
CDCl3): 173.76 (d, J = 4.1 Hz, CO), 130.02 (d, J = 4.1 Hz),
127.40−127.07 (m), 125.64, 121.54 (d, J = 9.3 Hz), 120.54 (t, J = 4.8
Hz), 52.69, 50.09 (d, J = 6.6 Hz), 39.39−37.22 (m), 21.74(2d, J = 3.5
Hz, CH3).
Isopropyl ((1,1-difluorobut-3-en-1-yl)(phenoxy)phosphoryl)-L-
alaninate (8b). Synthesized following general procedure 1 using
phenol (0.210 g, 2.23 mmol, 1 equiv) and L-alanine isopropyl ester
hydrogen chloride (0.314 g, 1.87 mmol, 1 equiv) to give product 8b
(0.165 g, 25%) as a colorless oil. δP NMR (202 MHz, CDCl3): 9.17
(dd, J = 101.1, 30.3 Hz), 8.46 (dd, J = 99.9, 38.0 Hz). δH NMR (500
MHz, CDCl3). 7.34 (m, 2H, Ar), 7.20 (m, 3H, Ar), 5.89 (m, 1H,
CH2CH), 5.29 (m, 2H, CH2CH), 4.99 (m, 1H, CH−iPr), 4.14−
3.99 (m, 1H, CH−NH), 3.68 (m, 1H, NH), 3.00−2.89 (m, 2H, 
CH−CH2), 1.35−1.17 (m, 9H, CH3−CH−NH, CH−iPr). δC NMR
(126 MHz, CDCl3): 172.68 (d, J = 5.9 Hz, CO), 149.46, 129.88 (d,
J = 4.2 Hz), 127.11 (d, J = 5.4 Hz), 125.46, 121.36 (d, J = 8.9 Hz),
120.40 (t, J = 4.9 Hz), 69.39 (d, J = 2.8 Hz, CH−iPr), 50.15, 38.63−
37.99 (m), 21.58 (d, J = 1.6 Hz), 21.44 (2 d, J = 3.2 Hz, CHCH3).
tert-Butyl ((1,1-difluorobut-3-en-1-yl)(phenoxy)phosphoryl)-L-
alaninate (8c). Synthesized following general procedure 1 using
phenol (0.210 g, 2.23 mmol, 1 equiv) and L-alanine tert-butyl ester
hydrogen chloride (0.340 g, 1.87 mmol, 1 equiv) to give product 8c
(0.320 g, 46%) as a colorless oil. δP NMR (202 MHz, CDCl3): 9.23
(dd, J = 101.0, 34.4 Hz), 8.52 (dd, J = 99.6, 36.0 Hz). δH NMR (500
MHz, CDCl3): 7.34 (m, 2H, Ar),7.21 (m, 3H, Ar), 5.89 (m, 1H,
CH2CH), 5.28 (m, 2H, CH2CH), 4.08−3.98 (m, 1H, CH−
NH), 3.67 (m, 1H, NH), 3.01−2.84 (m, 2H,CH−CH2), 1.42 (d, J
= 5.2 Hz,9H, tBu), 1.30 (d, J = 7.2 Hz, 3H, CH−CH3). δC NMR (126
MHz, CDCl3): 172.48 (d, J = 4.5 Hz, CO), 149.72, 129.99 (d, J =
2.1 Hz), 128.59−126.95 (m), 125.54, 121.46 (d, J = 9.2 Hz), 120.54
(t, J = 4.8 Hz), 82.32 (d, J = 5.8 Hz), 50.69 (d, J = 2.8 Hz, CH−NH),
38.80−38.12 (m), 27.99, 21.85 (2d, J = 3.1 Hz, CHCH3).
Benzyl ((1,1-difluorobut-3-en-1-yl)(phenoxy)phosphoryl)-L-alani-
nate (8d). Synthesized following general procedure 1 using phenol
(0.210 g, 2.23 mmol, 1 equiv) and L-alanine benzyl ester hydrogen
chloride (0.403 g, 1.87 mmol, 1 equiv) to give product 8d (0.350 g,
45% yield) as a colorless oil. δP NMR (202 MHz, CDCl3): 9.08 (dd, J
= 101.2, 45.4 Hz), 8.39 (dd, J = 100.1, 46.5 Hz). δH NMR (500 MHz,
CDCl3): 7.41−7.29 (m, 7H, Ar), 7.25−7.17 (m, 3H, Ar), 5.87 (m,
1H, CH2CH), 5.27 (m, 2H, CH2CH), 5.11 (m, 2H, −OCH2),
4.33−4.09 (m, 1H, CH−NH), 3.68 (m, 1H, NH), 2.93 (m, 2H, P−
CH2), 1.36 (d, J = 7.2 Hz, 3H, CH−CH3). δC NMR (126 MHz,
CDCl3): 173.15 (d, J = 3.2 Hz, CO), 149.68, 135.26 (d, J = 6.4
Hz), 130.01 (d, J = 4.1 Hz), 128.87−128.52 (m), 128.35 (d, J = 1.1
Hz), 127.38−127.03 (m), 125.62, 122.24−120.38 (m), 120.51, 67.49,
50.20, 38.74−38.07 (m), 21.96 (2 d, J = 3.5 Hz, CHCH3).
Methyl (((E)-1,1-difluoro-5-hydroxy-4-methylpent-3-en-1-yl)-
(phenoxy)phosphoryl)-L-alaninate (9a). Synthesized following gen-
eral procedure 2 using 8a (0.150 g, 0.45 mmol, 1 equiv) to give
product 9a (97 mg, 58%) as a colorless oil. δP NMR (202 MHz,
CDCl3) δ 9.27 (dd, J = 112.1, 18.4 Hz), 8.44 (dd, J = 126.4, 20.2 Hz).
δH NMR (500 MHz, CDCl3): 7.35 (m, 2H, Ar), 7.21 (m, 3H, Ar),
5.56 (m, 1H,CH), 4.18 (m, 1H, CH−NH), 4.07 (m, 2H,CH−
CH2), 3.75−3.46 (m, 4H, NH, OCH3), 3.10−2.79 (m, 2H, CH−
CH2), 1.83 (m, 1H, OH), 1.76 (s, 3H, CH3(CH2)CCH),1.37 (2 ×
d, J = 7.1 Hz, 3H, CH−CH3). δC NMR (126 MHz, CDCl3): 176.76,
141.38 (d, J = 7.6 Hz), 130.04 (d, J = 3.2 Hz), 125.65 (d, J = 4.0 Hz),
120.56 (d, J = 4.6 Hz), 120.47 (d, J = 4.7 Hz), 68.25 (d, J = 1.9 Hz),
52.80 (CH3−O), 50.09 (d, J = 4.1 Hz, CH−NH), 32.82, 21.82 (2 d, J
= 2.6 Hz, CHCH3), 14.15 (CH3). HRMS (ES+, m/z): calcd for (M +
Na)+ C16H22F2NO5NaP, 400.1101; found, 400.1109. HPLC (reverse-
phase) 0.5 mL/min MeOH/H2O 70:30 in 12 min, λ = 254 nm, Rt =
5.45 min (99%).
Isopropyl (((E)-1,1-difluoro-5-hydroxy-4-methylpent-3-en-1-yl)-
(phenoxy)phosphoryl)-L-alaninate (9b). Synthesized following gen-
eral procedure 2 using 8b (0.150 g, 0.41 mmol, 1 equiv) to give
product 9b (117 mg, 69%) as a colorless oil. δP NMR (202 MHz,
CDCl3): 9.30 (dd, J = 109.1, 34.4 Hz), 8.42 (dd, J = 111.1, 38.4 Hz).
δH NMR (500 MHz, CDCl3): 7.35 (m, 2H, Ar), 7.21 (m, 3H, Ar),
5.56 (m, 1H, CH), 5.00 (m, 1H, CH−iPr), 4.17−3.91 (m, 3H,
CH−NH, CH−CH2), 3.67 (m, 1H, NH), 3.08−2.75 (m, 2H, 
CH−CH2), 1.86 (m, 1H, OH), 1.70 (s, 3H, CH3(CH2)CCH),
1.34−1.19 (m, 9H, CH3−CH−NH, CH−iPr). δC NMR (126 MHz,
CDCl3): 173.09 (d, J = 6.8 Hz, CO), 141.37 (d, J = 7.9 Hz), 130.03
(d, J = 2.6 Hz), 125.60 (d, J = 4.4 Hz), 120.50 (dd, J = 10.6, 4.7 Hz),
113.79−113.43 (m), 69.71 (d, J = 4.5 Hz), 68.25, 50.29 (d, J = 9.6
Hz), 30.88−28.72 (m), 21.73 (d, J = 8.2 Hz), 21.84 (2d, J = 4.1 Hz,
CHCH3), 14.18 (CH3). HRMS (ES+, m/z): calcd. for (M + Na)
+
C18H26F2NO5NaP, 428.1414; found, 428.1414. HPLC (reverse-
phase) 0.5 mL/min MeOH/H2O 70:30 in 12 min, λ = 254 nm, Rt
= 5.46 min (97.5%).
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tert-Butyl (((E)-1,1-difluoro-5-hydroxy-4-methylpent-3-en-1-yl)-
(phenoxy)phosphoryl)-L-alaninate (9c). Synthesized following gen-
eral procedure 2 using 8c (0.150 g, 0.39 mmol, 1 equiv) to give
product 9c (105 mg, 63%) as a colorless oil. δP NMR (202 MHz,
CDCl3): 9.36 (dd, J = 109.1, 34.4 Hz), 8.48 (dd, J = 111.1, 36.4 Hz).
δH NMR (500 MHz, CDCl3): 7.36 (m, 2H, Ar), 7.22 (m, 3H, Ar),
5.56 (m, 1H, CH), 4.16−3.93 (m, 3H, CH−NH, CH−CH2),
3.63 (m, 1H, NH), 3.08−2.77 (m, 2H, CH−CH2), 1.90 (m, 1H,
OH), 1.71 (s, 3H, CH3(CH2)CCH), 1.43 (d, J = 5.2 Hz, 9H, tBu),
1.30 (2 × d, J = 7.1 Hz, 3H, CH−CH3). δC NMR (126 MHz,
CDCl3): 172.79 (d, J = 6.8 Hz, CO), 130.02, 125.56 (d, J = 5.8
Hz), 120.55 (d, J = 4.6 Hz), 120.47 (d, J = 4.4 Hz), 82.59, 68.26,
50.72 (d, J = 7.4 Hz, CH−NH), 32.97−32.80 (m), 28.02 (d, J = 1.1
Hz, 3 × CH3), 21.98 (2 d, J = 3.8 Hz, CHCH3), 14.16. HRMS (ES+,
m/z) calcd. for (M + Na)+ C19H28F2NO5NaP: 442.1571; found:
442.1578. HPLC (reverse-phase) 0.5 mL/min MeOH/H2O 80:20 in
12 min, λ = 254 nm, Rt = 4.87 min (96%).
Benzyl (((E)-1,1-difluoro-5-hydroxy-4-methylpent-3-en-1-yl)-
(phenoxy)phosphoryl)-L-alaninate (9d). Synthesized following gen-
eral procedure 2 using 8d (0.150 g, 0.36 mmol, 1 equiv) to give
product 9d (101 mg, 61%) as a colorless oil. δP NMR (202 MHz,
CDCl3): 9.21 (dd, J = 113.2, 22.3 Hz), 8.37 (dd, J = 111.1, 24.3 Hz).
δH NMR (500 MHz, CDCl3): 7.39−7.28 (m, 7H, Ar), 7.24−7.16 (m,
3H, Ar), 5.55 (m,1H, CH), 5.13 (m, 2H, OCH2), 4.27−4.14 (m,
1H, CH−NH), 4.06 (m, 2H,CH−CH2), 3.68 (m, 1H, NH), 3.05−
2.73 (m, 2H, CH−CH2), 1.80 (m, 1H, OH), 1.69 (s, 3H,
CH3(CH2)CCH), 1.35 (2 × d, J = 7.1 Hz, 3H, CH−CH3). δC (126
MHz, CDCl3): 173.38 (d, J = 7.9 Hz, CO), 149.71, 141.37 (d, J =
8.3 Hz), 130.04 (d, J = 3.1 Hz), 128.76 (d, J = 12.8 Hz), 128.35 (s),
125.63 (d, J = 5.5 Hz), 120.49 (dd, J = 13.7, 4.6 Hz), 113.75−113.34
(m), 68.25 (d, J = 2.4 Hz), 67.61, 50.22 (d, J = 8.0 Hz), 34.32−31.18
(m), 21.84 (d, J = 3.8 Hz, CHCH3), 14.15 (CH3). HRMS (ES+,m/
z): calcd for (M + Na)+ C22H26F2NO5NaP, 476.1414; found,
476.1421. HPLC (reverse-phase) 0.5 mL/min MeOH/H2O 70:30
in 12 min, λ = 254 nm, Rt = 6.58 min (96%).
In Silico Docking. Computational studies were performed using
the OpenEye molecular modelling software suite provided by the
OpenEye Scientific Software (http://www.eyesopen.com). An iMac
with Intel Core i5/2.9 GHz microprocessor, 8 GB RAM, and running
macOS operating system 10.14.1 was used to execute the docking
studies. The three-dimensional cocrystal structure of AMP with the
human Hint-1 was retrieved from the Protein Data Bank (PDB code
1KPF), and the site of AMP binding was identified as the docking
site.52 Omega2 was used to generate multiple conformers for
metabolite C using the default settings.53 FRED (fast rigid exhaustive
docking) implements a rigid docking approach to fit these conformers
into the predefined binding site and rank the poses by scoring
functions.54,55 The VIDA module was then used to visualize and
inspect the docked poses and identify key interactions between
metabolite C and Hint-1.
Serum Stability. The experiment was carried out according to a
published procedure,43 ProPAgens 4d or 9d (5.0 mg) in DMSO
(0.050 mL) and D2O (0.15 mL). After recording the control
31P
NMR at 37 °C, 0.30 mL of a freshly defrosted human serum aliquot
(code: H4522, Sigma, U.K.) was added to the sample, which was next
submitted to the 31P NMR experiments at 37 °C. The spectra were
recorded every 30 min over 12 h. 31P NMR recorded data were
processed and analyzed using the Bruker TopSpin 2.1 program.
In Vitro Carboxypeptidase Y Assay. The experiment was
carried out according to the published protocol.43 This involved
dissolving ProPAgens 94 (3.0 mg) in acetone-d6 (0.15 mL), followed
by addition of 0.30 mL of T TRIZMA buffer (pH 7.6). After
recording the control 31P NMR at 25 °C, a previously defrosted
carboxypeptidase Y aliquot (0.1 mg dissolved in 0.15 mL of
TRIZMA) was added to the sample, which was then immediately
submitted to the 31P NMR experiments (at 25 °C). The spectra were
recorded after 10 min, and every 1 h for 12 h.
Isolation of PBMCs from Healthy Donors. All healthy donors
participating in this study were aged over 21 and were recruited from
the Institute of Immunology and Immunotherapy, University of
Birmingham. Written informed consent was obtained from all donors
prior to any blood withdrawal, and ethical approval was obtained from
the NRES Committee West Midlands ethical board (REC reference
14/WM/1254). Approximately 50 mL of peripheral blood (PB) was
collected, and PB mononuclear cells (PBMCs) were extracted via a
ficoll gradient method using Lymphoprep reagent. A volume of 30−
35 mL of undiluted whole blood was carefully layered over 15 mL of
Lymphoprep, and the cells were then centrifuged at 1200g for 20 min
without brake. PBMCs were harvested, washed twice in PBS at 1900
rpm for 5 min, and counted manually using a hemocytometer. The
required number of cells was taken for experiments, and any excess
was frozen down with freezing media consisting of FCS +10% v/v
DMSO. The Vγ9Vδ2 T-cells were identified in all assays by flow
cytometric staining as Vγ9+ Vδ2+ population within the live (Zombie
Aqua viability dye) CD3+ gate.
In Vitro Vγ9Vδ2 T-Cell Activation Assays. PBMCs were seeded
out into round-bottom 96-well plates at 5 × 105 cells in a total volume
of 200 μL per well, and stimulated with zoledronate and HMBPP
(concentrations range 1 pM to 100 μM) and HMBPP ProPAgens,
initially at a concentration range of 100 μM to 10 pM, and then,
compounds 4d and 9d were selected and tested at 1 aM to 100 μM in
a separate experiment. The cells were incubated at 37 °C/5% CO2
overnight and were stained by flow cytometry to assess Vγ9Vδ2 T-cell
activation on the following day. The staining panel included viability
dye (Zombie Aqua; 1:400), CD3 (BV421; 1:100), Vγ9 (PEcy5;
1:400), Vδ2 (APC; 1:400), CD8 (BV650; 1:100), CD69 (PE; 1:25),
and CD25 (FITC; 1:100). All samples were acquired using a
LSRFortessa X20 (BD Biosciences), and all data were analyzed via
FlowJo v10 and GraphPad Prism software.
Retroviral Transduction of T24 Cells with GFP. For
production of retrovirus encoding green fluorescent protein (GFP),
Phoenix cells were transiently transfected with GFP-retroviral vector
(kindly provided by Prof. C. Baum, Hannover Medical School,
Hannover, Germany) and pCl ampho using Fugene 6 (Promega).
The retrovirus particles were collected after 48 h of transfection and
were then immobilized to a fibronectin (RetroNectin, Takara)-coated
nontissue culture-treated plate (Corning). Subsequently, T24 bladder
carcinoma cells (ATCC HTB4) were incubated with the immobilized
retrovirus for 72 h at 37 °C. Cells were then acquired on a BD
LSRFortessa X20 (BD Biosciences), and GFP expression data were
analyzed with FlowJo V10.1.
Cytotoxicity Assay. Prior to carrying out the assay, Vγ9Vδ2 T-
cells were expanded ex vivo from healthy donor PBMCs with 5 μM of
zoledronate and the addition of 100 U/mL IL2 every 2−3 days over a
period of 14 days. On the final day (day 14), GFP + T24 bladder
carcinoma cells were cultured for 4 h in the presence of 10 pM
ProPAgens or 10 pM HMBPP in round-bottom nontissue culture-
treated plates. After washing the plates three times with RPMI
medium, expanded Vγ9Vδ2 T-cells were then added, and the
cocultures were incubated for 18 h at 37 °C. Cells were then labelled
with eFluor 780 fixable viability dye (Invitrogen). Samples were
subsequently acquired on a BD LSRFortessa X20 (BD Biosciences),
and the data were analyzed with FlowJo V10.1 and Graphpad PRISM
7 (Graphpad Software Inc). The percentage of killing was determined
by calculating the number of fixable viability dye + GFP + T24 (dead
cells) of the total number of GFP + T24 cells. This assay was
performed with n = 3 donors.
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Bates, P. A.; Kimmel, B.; Knowles, T. J.; Kunzmann, V.; Walter, L.;
Jeeves, M.; Mohammed, F.; Willcox, B. E.; Herrmann, T.
Butyrophilin-2A1 directly binds germline-encoded regions of the
Vγ9Vδ2 TCR and is essential for phosphoantigen sensing. Immunity
2020, 52, 487−498.
(19) Hsiao, C.-H. C.; Lin, X.; Barney, R. J.; Shippy, R. R.; Li, J.;
Vinogradova, O.; Wiemer, D. F.; Wiemer, A. J. Synthesis of a
phosphoantigen prodrug that potently activates Vγ9Vδ2 T-lympho-
cytes. Chem. Biol. 2014, 21, 945−954.
(20) Davey, M. S.; Malde, R.; Mykura, R. C.; Baker, A. T.; Taher, T.
E.; Le Duff, C. S.; Willcox, B. E.; Mehellou, Y. Synthesis and biological
evaluation of (E)-4-hydroxy-3-methylbut-2-enyl phosphate (HMBP)
aryloxy triester phosphoramidate prodrugs as activators of Vγ9/Vδ2
T-cell immune responses. J. Med. Chem. 2018, 61, 2111−2117.
(21) Eberl, M.; Hintz, M.; Reichenberg, A.; Kollas, A.-K.; Wiesner,
J.; Jomaa, H. Microbial isoprenoid biosynthesis and human γδ T cell
activation. FEBS Lett. 2003, 544, 4−10.
(22) Reichenberg, A.; Hintz, M.; Kletschek, Y.; Kuhl, T.; Haug, C.;
Engel, R.; Moll, J.; Ostrovsky, D. N.; Jomaa, H.; Eberl, M. Replacing
the pyrophosphate group of HMB-PP by a diphosphonate function
abrogates its potential to activate human γδ T cells but does not lead
to competitive antagonism. Bioorg. Med. Chem. Lett. 2003, 13, 1257−
1260.
(23) Gossman, W.; Oldfield, E. Quantitative structure–activity
relations for γδ T cell activation by phosphoantigens. J. Med. Chem.
2002, 45, 4868−4874.
(24) van Beek, E.; Pieterman, E.; Cohen, L.; Löwik, C.; Papapoulos,
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